CClinicalTrials.gg
CompletedNCT00718978Updated Sep 9, 2008

Clinical Application of Autologous Three-Cellular Cultured Skin Substitutes (CSS)

An interventional study of CSS grafting in Burns, Ulcers and Giant Nevi, sponsored by University of Roma La Sapienza. Completed at 1 site in Italy. Open to participants aged 1 Year to 70 Years. Per ClinicalTrials.gov, last updated 2008-09-09.

Sponsored by University of Roma La Sapienza · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
1 Year to 70 Years
Sex
All
01

Study summary

The aim of this work was to present the investigators experience in the use of autologous three-cellular cultured skin substitutes (CSS) consisting of cultured keratinocytes, melanocytes and fibroblasts attached to a scaffold of hyaluronic acid. This method represents a surgical alternative in the treatment of a variety of pathologies, including burns, ulcers and giant nevi.

Read the detailed description

Background and Objective:

Permanent wound closure remains a limiting factor in the closure of extensive, full-thickness loss of substance. The aim of this work was to present our experience in the use of autologous three-cellular cultured skin substitutes (CSS) consisting of cultured keratinocytes, melanocytes and fibroblasts attached to a scaffold of hyaluronic acid. This method represents a surgical alternative in the treatment of a variety of pathologies, including burns, ulcers and giant nevi.

Methods:

CSS were obtained from full-thickness skin biopsies collected after enrollment of 11 patients in a study protocol approved by the local Institutional Review Boards of the "La Sapienza" University of Rome. CSS consisted of a structure characterized by the presence of a pluristratified epithelial cell surface with melanocytes (relation 1/20) and a basement of fibroblasts kept together by an esterified hyaluronic acid scaffold that can be surgically manipulated, and is gradually reabsorbed after implantation and substituted by the host connectival stroma.

02

Conditions studied

  • Burns
  • Ulcers
  • Giant Nevi

Keywords

  • bioengineered
  • ski
  • keratinocytes
  • fibroblasts
  • skin
  • culture
  • autologous
  • CSS
  • full-thickness loss of substance from:
  • burns
  • ulcers
  • giant nevi
  • cicatricial outcomes
03

In context

Lead sponsor

University of Roma La Sapienza is the lead sponsor of 388 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • of extensive full-thickness loss of substance

Exclusion criteria

Exclusion Criteria:

  • location: face
  • all contra indications for surgery
  • coagulation disorders
  • infection
  • allergic reactions
  • collagenopathies
  • malignant cancer and chemotherapy
  • immunodeficiencies
  • diabetes
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Other
    B

    the investigators grafted sheets based on the HYAFF11p80® scaffold (the one with the lowest degree of esterification)

    Procedure: CSS grafting

  • Other
    A

    the investigators grafted sheets based on the HYAFF11® scaffold (the one with the highest degree of esterification).

    Procedure: CSS grafting

  • Other
    A-B

    the investigators grafted sheets based on the HYAFF11® scaffold and sheets based on the HYAFF11p80 ® scaffold

    Procedure: CSS grafting

Interventions

  • ProcedureCSS grafting

    grafting of autologous three-cellular cultured skin substitutes (CSS) consisting of cultured keratinocytes, melanocytes and fibroblasts attached to a scaffold of hyaluronic acid (HYAFF11® and HYAFF11p80®) obtained from full-thickness skin biopsies to repair full-thickness loss of substance

06

What researchers measure

Primary outcomes

  1. CSS graft take compare to the take of autografts confirmed by histological and macroscopic appearance

    Time frame: 3 years maximum

Secondary outcomes

  1. Final aesthetic outcome determined by the take of melanocytes

    Time frame: 3 years maximum

07

Study locations

1 site
  • Dipartimento Malattie Cutanee-Veneree e Chirurgia Plastica e Ricostruttiva universita' "La Sapienza" Roma
    Roma, 00161, Italy
08

References and documents

Publications

  • Scuderi N, Onesti MG, Bistoni G, Ceccarelli S, Rotolo S, Angeloni A, Marchese C. The clinical application of autologous bioengineered skin based on a hyaluronic acid scaffold. Biomaterials. 2008 Apr;29(11):1620-9. doi: 10.1016/j.biomaterials.2007.12.024. Epub 2008 Jan 16. PubMed 18201759 ↗
  • Scuderi N, Anniboletti T, Carlesimo B, Onesti MG. Clinical application of autologous three-cellular cultured skin substitutes based on esterified hyaluronic acid scaffold: our experience. In Vivo. 2009 Nov-Dec;23(6):991-1003. PubMed 20023246 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 9, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00718978
Lead sponsor
University of Roma La Sapienza
First posted
Jul 21, 2008
Start date
Jun 2003
Primary completion
Jul 2004
Completion
Jul 2007
Last update
Sep 9, 2008

Study contacts

nicolo' scuderi, professor
study chair · universita "la Sapienza" Roma

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion